Role of complementary and alternative medicine in the care of patients with breast cancer: Report of the European Society of Mastology (EUSOMA) Workshop, Florence, Italy, December 2004

European Journal of Cancer

Volumn 42, Issue 12, 2006, Pages 1702-1710

  Baum, Michael ^a   Ernst, Edzard ^b   Lejeune, Stéphane ^c   Horneber, Markus ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

^c EORTC DATA CENTER   (Belgium)

^d Medizinische Klinik 5   (Germany)

Author keywords

Breast cancer; Complementary and alternative medicine

Indexed keywords

ACUPUNCTURE; ALTERNATIVE MEDICINE; AROMATHERAPY; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RESEARCH; CANCER THERAPY; CRANIOSACRAL THERAPY; EUROPE; HEALING; HUMAN; ITALY; MASSAGE; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RELAXATION TRAINING; SPIRITUAL HEALING; TIME SERIES ANALYSIS; YOGA;

BREAST NEOPLASMS; COMPLEMENTARY THERAPIES; CONGRESSES; FEMALE; HUMANS; ITALY; REVIEW LITERATURE;

EID: 33746634321     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.02.020     Document Type: Article

References (72)

1. McGrath P. Creating a language for 'spiritual pain' through research: a beginning. Support Care Cancer 10 8 (2002) 637-646
2. Tatsumura Y., Maskarinec G., Shumay D.M., and Kakai H. Religious and spiritual resources, CAM, and conventional treatment in the lives of cancer patients. Altern Ther Health Med 9 3 (2003) 64-71
3. Newell S.A., Sanson-Fisher R.W., and Savolainen N.J. Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. J Natl Cancer Inst 94 8 (2002) 558-584
4. Peto R., Boreham J., Clarke M., Davies C., and Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355 9217 (2000) 1822
5. Humphrys J. Lost for words. The mangling and manipulating of the English language (2004), Hodder & Stoughton, London
6. Shorter Oxford English dictionary, third ed. Oxford: Oxford University Press; 1944.
7. Koestler A. Janus: a summing up (1978), Picador, London
8. Turner-Cobb J., Sephton S.E., and Speigel D. Psycho-social effect on immune function and disease progression in cancer: human studies. In: Ader C., Felton D., and Cohen C. (Eds). Psychoneuroimmunology (2001), Academic Press, New York
9. American Cancer Society I. An overview of complementary and alternative therapies. Available from: http://www.cancer.org/docroot/ETO/content/ETO_5_1_Introduction.asp.
10. Cochrane Complementary Medicine Field CAM definition. 2004. Available from: http://www.compmed.umm.edu/compmed/cochrane/cochrane.htm.
11. Horneber MA, Büschel G, Less DB, Ritter E, Dennert G. The prevalence of unconventional methods in cancer patients: a systematic review. 2006 (in press).
12. Labriola D., and Livingston R. Possible interactions between dietary antioxidants and chemotherapy. see comments. Oncology (Huntingt) 13 7 (1999) 1003-1008
13. McCune J.S., Hatfield A.J., Blackburn A.A., Leith P.O., Livingston R.B., and Ellis G.K. Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 12 (2004) 454-462
14. Sparreboom A., Cox M.C., Acharya M.R., and Figg W.D. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22 12 (2004) 2489-2503
15. Werneke U., Earl J., Seydel C., Horn O., Crichton P., and Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 90 2 (2004) 408-413
16. Mills E., Ernst E., Singh R., Ross C., and Wilson K. Health food store recommendations: implications for breast cancer patients. Breast Cancer Res 5 6 (2003) R170-R174
17. Kumar N.B., Hopkins K., Allen K., Riccardi D., Besterman-Dahan K., and Moyers S. Use of complementary/integrative nutritional therapies during cancer treatment: implications in clinical practice. Cancer Control 9 3 (2002) 236-243
18. Izzo A.A., and Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61 15 (2001) 2163-2175
19. Balneaves L.G., Kristjanson L.J., and Tataryn D. Beyond convention: describing complementary therapy use by women living with breast cancer. Patient Educ Couns 38 2 (1999) 143-153
20. Tasaki K., Maskarinec G., Shumay D.M., Tatsumura Y., and Kakai H. Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients' perspectives. Psycho Oncology 11 3 (2002) 212-220
21. Söllner W., Maislinger S., and Kappauf H. How to improve communication between physicians and cancer patients about use of complementary and alternative medicine?. Psycho Oncology 12 2 (2003) 203-204
22. Horneber M., Büschel G., Kaiser G., Kappauf H., Wilhelm M., and Gallmeier W.M. Unkonventionelle Verfahren - Chancen für die Arzt-Patient-Beziehung (Unconventional methods. Chances for the physician-patient relationship). Onkologe 9 12 (2003) 1335-1342
23. Weiger W.A., Smith M., Boon H., Richardson M.A., Kaptchuk T.J., and Eisenberg D.M. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 137 11 (2002) 889-903
24. Horneber M.A., Büschel G., Kappauf H., Kaiser G., and Gallmeier W.M. Advising inquirers about unconventional cancer therapies. Onkologie 22 Suppl 1 (1999) 238
25. Shilling V., Jenkins V., and Fallowfield L. Factors affecting patient and clinician satisfaction with the clinical consulation: can communication skills training for clinicians improve satisfaction?. Psycho Oncology 12 (2003) 599-611
26. Fallowfield L., Jenkins V., Farewell V., and Solis-Trapala I. Enduring impact of communication skills training: results of a 12-month follow-up. Br J Cancer 89 8 (2003) 1445-1449
27. Priestman T.J., and Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1 7965 (1976) 899-900
28. Münstedt K., Entezami A., Wartenberg A., and Kullmer U. The attitudes of physicians and oncologists towards unconventional cancer therapies (UCT). Eur J Cancer 36 16 (2000) 2090-2095
29. Rose A. A comparison of conventional and alternative practitioners' views of the communication process in cancer care. Psycho Oncology 8 (1999) 11
30. Gray R.E., Greenberg M., Fitch M., et al. A strategy for informing patients and health professionals about unconventional cancer therapies. J Cancer Educ 13 1 (1998) 31-38
31. Sirois F.M. Treatment seeking and experience with complementary/alternative medicine: a continuum of choice. J Altern Complement Med 8 2 (2002) 127-134
32. Sirois F.M., and Gick M.L. An investigation of the health beliefs and motivations of complementary medicine clients. Soc Sci Med 55 6 (2002) 1025-1037
33. Ritvo P., Irvine J., Katz J., Matthew A., Sacamano J., and Shaw B.F. The patient's motivation in seeking complementary therapies. Patient Educ Couns 38 2 (1999) 161-165
34. Truant T., and Bottorff J.L. Decision making related to complementary therapies: a process of regaining control. Patient Educ Couns 38 2 (1999) 131-142
35. Brown P.J., and Carney P.A. Health beliefs and alternative medicine: a qualitative study of breast cancer patients. J Cancer Educ 11 4 (1996) 226-229
36. Vincent C., and Furnham A. Why do patients turn to complementary medicine? An empirical study. Br J Clin Psychol 35 Pt 1 (1996) 37-48
37. Daugherty C.K., Fitchett G., Murphy P.E., et al. Trusting God and medicine: spirituality in advanced cancer patients volunteering for clinical trials of experimental agents. Psychooncology 14 2 (2005) 135-146
38. de Moulin D. A short history of breast cancer (1989), Springer, Dordrecht
39. Lewison E.F. Spontaneous regression of breast cancer. Natl Cancer Inst Monogr 44 (1976) 23-26
40. Ross M.B., Buzdar A.U., Hortobagyi G.N., and Lukeman J.M. Spontaneous regression of breast carcinoma: follow-up report and literature review. J Surg Oncol 19 1 (1982) 22-24
41. Brady M.J., Peterman A.H., Fitchett G., and Cella D. The expanded version of the Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being Scale (FACIT-Sp-Ex): Initial report of psychometric properties. Ann Behav Med 21 (1999) 129
42. Steer C.J., and Lee C. Addressing spiritual care: calling for help. J Clin Oncol 22 23 (2004) 4856-4858
43. Sollner W., DeVries A., Steixner E., et al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling?. Br J Cancer 84 2 (2001) 179-185
44. Matthews D.A., McCullough M.E., Larson D.B., Koenig H.G., Swyers J.P., and Milano M.G. Religious commitment and health status: a review of the research and implications for family medicine. Arch Fam Med 7 (1998) 118-124
45. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995;41(10):1403-1409.
46. Canter P.H., Thompson Coon J., and Ernst E. Cost effectiveness of complementary treatments in the United Kingdom: systematic review. Br Med J 331 (2005) 880-881
47. Ernst E, Schmidt K, Baum M. Complementary/alternative therapies for the treatment of breast cancer. A systematic review of randomised clinical trials and critique of current terminology. 2005 (in press).
48. Rainer H., Moser K., and Bettelheim P. [Randomized study: chemotherapy versus chemotherapy plus transfer factor in metastasized breast neoplasm]. Verh Dtsch Ges Inn Med 84 (1978) 604-606
49. Ost B. Remissionserhaltung nicht-metastasierter Mammakarzinome unter Factor AF2. Dtsch Zschr Onkol 21 (1989) 102-104
50. Spiegel D., Kraemer H.C., Bloom J.R., and Gottheil E. Effect of Psychosocial Treatment on Survival of Patients with Metastatic Breast Cancer. Lancet 14 (1989) 888-891
51. Adachi I. Supporting therapy with Shi Quan Da Bu Tang in advanced breast cancer patients. Biomed Res 11 (1990) 25-32
52. Pavesi L. Fluorouracil (F), with and without high-dose folinic acid (HDFA) plus Epirubicin (E) and Cyclophosphamide (C): FEC versus HDFA-FEC plus or minus Thymostimulin (TS) in metastatic breast cancer: results of a multicenter study. Eur J Cancer 29 A suppl (1993) S77
53. Lissoni P., Barni S., Tancini G., et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69 1 (1994) 196-199
54. Ilnyckyj A., Farber J., Cheang M.C., and Weinerman B.H. A randomised controlled trial of psychotherapeutic intervention in cancer patients. Ann RCPSC 27 (1994) 93-96
55. Cunningham A.J., Edmonds C.V., Jenkins G.P., Pollack H., Lockwood G.A., and Warr D. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psycho Oncology 7 6 (1998) 508-517
56. Edelman S., Lemon J., Bell D.R., and Kidman A.D. Effects of group CBT on the survival time of patients with metastatic breast cancer. Psychooncology 8 6 (1999) 474-481
57. Lissoni P., Barni S., Mandala M., et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35 12 (1999) 1688-1692
58. Walker L.G., Walker M.B., Ogston K., et al. Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. Br J Cancer 80 1-2 (1999) 262-268
59. Goodwin P.J., Leszcz M., Ennis M., et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 345 24 (2001) 1719-1726
60. Kissane D.W., Love A., Hatton A., et al. Effect of cognitive-existential group therapy on survival in early-stage breast cancer. J Clin Oncol 22 21 (2004) 4255-4260
61. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
62. Vickers A.J. Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. J R Soc Med 89 6 (1996) 303-311
63. Molassiotis A., Yung H.P., Yam B.M., Chan F.Y., and Mok T.S. The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial. Support Care Cancer 10 3 (2002) 237-246
64. Wong R.K., Jones G.W., Sagar S.M., Babjak A.F., and Whelan T. A Phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 57 2 (2003) 472-480
65. Wilkinson S., Aldridge J., Salmon I., Cain E., and Wilson B. An evaluation of aromatherapy massage in palliative care. Palliat Med 13 5 (1999) 409-417
66. Hadfield N. The role of aromatherapy massage in reducing anxiety in patients with malignant brain tumours. Int J Palliat Nurs 7 6 (2001) 279-285
67. Roffe L., Schmidt K., and Ernst E. A systematic review of guided imagery as an adjuvant cancer therapy. Psychooncology 14 8 (2005) 607-617
68. Ernst E., Eisenburg D., and Pittler M. The desktop guide to complementary and alternative medicine an evidence-based approach (2001), C.V. Mosby, Edinburgh
69. Yoo H.J., Ahn S.H., Kim S.B., Kim W.K., and Han O.S. Efficacy of progressive muscle relaxation training and guided imagery in reducing chemotherapy side effects in patients with breast cancer and in improving their quality of life. Support Care Cancer 13 10 (2005) 826-833
70. Mock V., Frangakis C., Davidson N.E., et al. Exercise manages fatigue during breast cancer treatment: A randomized controlled trial. Psychooncology 14 6 (2005) 464-477
71. Pommier P., Gomez F., Sunyach M.P., D'Hombres A., Carrie C., and Montbarbon X. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol 22 8 (2004) 1447-1453
72. Semiglasov V.F., Stepula V.V., Dudov A., Lehmacher W., and Mengs U. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 24 2C (2004) 1293-1302